newsfilter.io
Oct 9, 2026, 5:00 PM ETHealthcare

Cosmos Health — Nine Months Ended September 30, 2026 Earnings Summary

COSMCOSMOS HEALTH INC
Source

Financial Performance

  • Preliminary revenue for the nine months ended September 30, 2026, was approximately $54.3 million, a 19% increase ($8.7 million) compared to $45.6 million in the same period of 2025.
  • Preliminary revenue for the third quarter of 2026 was approximately $17.4 million, a 2% increase over the $17.1 million recorded in Q3 2025 and a 40% increase over the $12.4 million recorded in Q3 2024.
  • Nine-month 2026 revenue nearly matches the full-year 2024 revenue of $54.4 million and represents 83% of the record full-year 2025 revenue of $65.3 million.
  • Revenue growth over the first nine months of 2024 was 35%.
  • The figures are preliminary and unaudited.

Guidance and Future Outlook

  • The Company reaffirmed its full-year 2026 revenue outlook to surpass $90 million, representing approximately 38% growth over 2025.
  • The fourth quarter of 2026 is expected to be the strongest quarter in the Company's history.
  • Q4 2026 growth is supported by contract manufacturing orders, seasonal strength in distribution, and accelerating sales in the United States.

Business Segments and Product Lines

  • Growth occurred across all core segments: contract manufacturing, pharmaceutical distribution, and proprietary brands.
  • Contract manufacturing at Cana Laboratories reached a record production pipeline of more than 32.7 million units.
  • Pharmaceutical distribution at CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies.
  • Proprietary brands (including Sky Premium Life, C-Scrub, and C-Sept) grew in established markets and expanded into new global territories and channels.
  • Sales momentum in the United States continued to build.

Management Commentary and Tone

  • CEO Greg Siokas stated that the Company delivered in nine months what previously took a full year in 2024.
  • Management noted that growth is coming from every part of the business, with record levels in the contract manufacturing pipeline and distribution volumes.
  • The tone emphasized that infrastructure built over the past several years is supporting business growth as the Company enters the final quarter with momentum.

Other Key Points

  • Every quarter of 2026 (Q1, Q2, and Q3) set a record for its respective period, exceeding the highest revenue previously reported for those quarters.
  • The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®.
  • Cosmos Health manufactures products in the European Union through Cana Laboratories S.A., which is licensed under European GMP and certified by the EMA.
  • The Company distributes pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK.
  • The Company has established R&D partnerships targeting obesity, diabetes, and cancer, utilizing AI drug repurposing technologies.
  • The Company entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA.
  • The Company has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.
  • Complete third-quarter results will be reported in the Quarterly Report on Form 10-Q for the period ended September 30, 2026.